metformin in treatment of clomiphene citrateresistant polycystic ovary syndrome: a prospective randomized controlled study
Departures from the protocol can reduce the medicine's effect and increase the chance of gastrointestinal symptoms
Sprecher E, Bergman R, Meilick A, Kerner H, Manov L, Reiter I et al
To test the possibility, we developed a rat model with hyperlipidemia and treated the rats with Sal A
With FDA approval, resmetirom, a liver-targeted thyroid hormone receptor- (THR) selective agonist, changes the MASH drug development landscape
Remember, it takes a few months to acclimate your body to the medication and titrate up in dosage to really see results